Key facts
- It has raised $15.8M; the latest was Later Stage VC ($15.8M) in Dec 2024.
- Notable investors include European Innovation Council, Emergys (France), Horizon Europe.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cherry Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Cherry Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cherry Biotech
Developer of microfluidic technology designed to culture and mimic any human organ in physio-pathological conditions. The company also offers temperature controllers for fast temperature shifts and next-generation 3D cell culture technologies, enabling clinicians to recapitulate the human cell microenvironment dedicated to drug development and toxicity.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2014
- Employees
- 23
- Website
- cherrybiotech.com/
- Ownership
- Privately Held (backing)
Cherry Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cherry Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cherry Biotech in its N-PORT filings yet. We sweep new filings monthly.